New to Meducation?
Sign up
Already signed up? Log In
view moderators

AcuteCoronarySyndrome

Category

Preview
0
1

Advancing Acute Coronary Syndrome Assessment: Role of Cardiac Troponin CME/CE

This activity is intended for cardiologists, emergency medicine physicians, nurses, and primary care physicians interested in the care of patients with ACS.  
medscape.org
almost 4 years ago
Preview
0
0

Newer antiplatelet agents in acute coronary syndrome

Dual antiplatelet therapy comprising aspirin and a purinergic P2Y12 receptor inhibitor has long been the standard of care in patients with acute coronary syndrome (ACS). Clopidogrel is the most commonly used P2Y12 inhibitor,1 but its usefulness has been questioned, with 25-30% of patients achieving <25% inhibition of platelet activity. Moreover, onset (4-6 hours, even after a loading dose) and offset (5-7 days, the lifetime of platelets) of its activity are relatively slow. This slow offset is due to its irreversible binding to the P2Y12 receptor and may assume importance in patients with bleeding complications or in those requiring urgent surgical intervention. Slow onset is disadvantageous in patients with ACS, owing to the potential for propagation of thrombus in the interval until P2Y12 inhibition occurs.  
feeds.bmj.com
almost 4 years ago
Preview
0
0

Newer antiplatelet agents in acute coronary syndrome

Dual antiplatelet therapy comprising aspirin and a purinergic P2Y12 receptor inhibitor has long been the standard of care in patients with acute coronary syndrome (ACS). Clopidogrel is the most commonly used P2Y12 inhibitor,1 but its usefulness has been questioned, with 25-30% of patients achieving <25% inhibition of platelet activity. Moreover, onset (4-6 hours, even after a loading dose) and offset (5-7 days, the lifetime of platelets) of its activity are relatively slow. This slow offset is due to its irreversible binding to the P2Y12 receptor and may assume importance in patients with bleeding complications or in those requiring urgent surgical intervention. Slow onset is disadvantageous in patients with ACS, owing to the potential for propagation of thrombus in the interval until P2Y12 inhibition occurs.  
feeds.bmj.com
almost 4 years ago
Preview
0
0

Newer antiplatelet agents in acute coronary syndrome

Dual antiplatelet therapy comprising aspirin and a purinergic P2Y12 receptor inhibitor has long been the standard of care in patients with acute coronary syndrome (ACS). Clopidogrel is the most commonly used P2Y12 inhibitor,1 but its usefulness has been questioned, with 25-30% of patients achieving <25% inhibition of platelet activity. Moreover, onset (4-6 hours, even after a loading dose) and offset (5-7 days, the lifetime of platelets) of its activity are relatively slow. This slow offset is due to its irreversible binding to the P2Y12 receptor and may assume importance in patients with bleeding complications or in those requiring urgent surgical intervention. Slow onset is disadvantageous in patients with ACS, owing to the potential for propagation of thrombus in the interval until P2Y12 inhibition occurs.  
feeds.bmj.com
almost 4 years ago
Preview
0
0

Bivalirudin in the treatment of acute coronary syndrome

Bivalirudin was heralded as the successor to heparin. It is a direct thrombin inhibitor with a more predictable dose response than heparin, a short half life of 22 minutes, and the ability to bind circulating and clot bound thrombin. But does it have genuine advantages over heparin in patients having percutaneous coronary interventions (PCI) for acute coronary syndrome or is it just expensive dilute heparin?  
feeds.bmj.com
almost 4 years ago
Preview
0
3

Bivalirudin in the treatment of acute coronary syndrome

Bivalirudin was heralded as the successor to heparin. It is a direct thrombin inhibitor with a more predictable dose response than heparin, a short half life of 22 minutes, and the ability to bind circulating and clot bound thrombin. But does it have genuine advantages over heparin in patients having percutaneous coronary interventions (PCI) for acute coronary syndrome or is it just expensive dilute heparin?  
feeds.bmj.com
almost 4 years ago
Www.bmj
0
1

Bivalirudin in the treatment of acute coronary syndrome

Bivalirudin was heralded as the successor to heparin. It is a direct thrombin inhibitor with a more predictable dose response than heparin, a short half life of 22 minutes, and the ability to bind circulating and clot bound thrombin. But does it have genuine advantages over heparin in patients having percutaneous coronary interventions (PCI) for acute coronary syndrome or is it just expensive dilute heparin?  
feeds.bmj.com
almost 4 years ago
Preview
0
3

Risk Stratification vs Published Guidelines in ACS

Is unstructured risk assessment by emergency physicians as accurate as the recommended guidelines for predicting acute coronary syndrome?  
medscape.com
almost 4 years ago
Preview
0
3

CT Angiography for Suspected ACS in the Era of hs-Troponins

Does a diagnostic strategy supplemented by early coronary CT angiography offer an advantage over diagnosis via high-sensitivity troponin assay in suspected acute coronary syndrome?  
medscape.com
over 3 years ago
Preview
0
1

The Year in Cardiology 2015: Acute Coronary Syndromes

What progress was made during the year 2015 towards our understanding and management of acute coronary syndrome?  
medscape.com
over 3 years ago
Preview
0
3

Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Can lipid-lowering therapy with ezetimibe plus simvastatin improve clinical outcomes among survivors of acute coronary syndromes?  
medscape.com
over 3 years ago
Preview
0
1

R.E.B.E.L. EM - Does My Patient with Chest Pain Have Acute Coronary Syndrome? - emdocs

What is known about chest pain is that it is a common complaint presenting to EDs all over the world, but only a small percentage of these patients will be ultimately diagnosed with Acute Coronary Syndrome (ACS).   
emdocs.net
over 3 years ago
Preview
0
1

ALiEMU CAPSULES Module 6: Pharmacology of Acute Coronary Syndromes

A summary of the Pharmacology of Acute Coronary Syndromes from module 6 of the ALiEMU CAPSULES series is listed.  
aliem.com
over 3 years ago
Preview
0
8

Cardiac Troponin: Defining the 99th percentile reference limit for MI CME/CE

This activity is intended for cardiologists, emergency medicine physicians, nurses, and primary care physicians interested in the care of patients with acute coronary syndrome (ACS).  
medscape.org
over 3 years ago